Surprised By Recursion Pharmaceuticals’ Slide? What Investors Overlooked

If you only glanced at Recursion Pharmaceuticals’ headlines this year, the story looked encouraging. Clinical trial updates, fresh FDA engagement and new partner milestones suggested a platform turning scientific promise into concrete progress. Holding Recursion Pharmaceuticals over the past year would have meant a 40.9% loss, including dividends. If you had been weighing a position back in October 2025, which early signals mattered most before that slide became clear?

A Narrative on Simply Wall St is one investor's written case for a company, with its growth, margin and multiple assumptions spelled out. Those assumptions imply an estimated Fair Value.

Recursion Pharmaceuticals is not the only name tied to this theme. Zero in on 37 AI small caps and compare how each one is priced.

The Two Stories Investors Had To Weigh On Recursion Pharmaceuticals

The shares cost US$6.36 at the start of the period, and anyone looking at Recursion Pharmaceuticals had to decide which future felt more realistic for that price.

On the optimistic side, the bullish Narrative put Fair Value at US$10 and leaned on Recursion OS 2.0. Supporters focused on an assumed 84.2% revenue growth rate and a shift toward a 14.2% profit margin within 3 years.

The cautious view set Fair Value at US$3 and highlighted execution strain. That bearish case accepted only 16.5% revenue growth and pointed to high R&D spending and the risk that heavy cash burn could force dilution.

What The Results Changed For Recursion Pharmaceuticals

Recursion Pharmaceuticals reported Q2 2026 revenue of US$7.7 million compared with US$19.2 million a year earlier, which challenged the bullish case that leaned on rapid top line expansion. Net loss excluding extra items narrowed from US$171.9 million to US$131.0 million, so profitability moved in the right direction but the business was still loss making. The evidence cut both ways.

The key assumption investors needed to track was how quickly heavy R&D spend would turn into scalable revenue. For a similar stock today, you would compare management growth claims with reported sales and the size of the ongoing loss in each set of results.

What Recursion’s Lower Price Now Asks You To Believe

Recursion Pharmaceuticals trades at US$3.46 today after a 40.9% share price fall over the past year. The current bullish Narrative places Fair Value above that level, based on the idea that the drug discovery platform is already converting partnerships and data into meaningful business traction.

For today’s buyer, the key question is whether the clinical readouts, cash runway and partner milestones described in the Narrative really mark a durable shift toward a commercial TechBio model rather than a brief repricing bounce.

"With validated clinical data, significant milestone payments from partners like Roche, and a cash runway extending through 2027, Recursion is transitioning into a commercial-stage TechBio leader."

That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for

Looking One Step Beyond Recursion

Recursion keeps pointing to its drug discovery platform. You might ask what happens after a successful molecule leaves that kind of engine.

Weight loss and diabetes treatments show how huge that downstream need can become. Patients want therapies that manage blood sugar, reduce weight and still fit everyday life.

Another large drug maker already focuses on that specific demand. It develops injectable and pill based treatments targeting obesity, diabetes and related conditions.

Those medicines rely on years of trial data and broad regulatory work. If more effective compounds emerge, the role of that business could shift again.

That argument has a Narrative and a number behind it. → See the company one Narrative values 18% above its price

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com